Alnylam Pharmaceuticals, Inc.
ALNY· Nasdaq
ALNYAlnylam Pharmaceuticals, Inc.
Source filing unavailable
| Metric | Q3 2010 | Q3 2009 |
|---|---|---|
| Revenue | $27.67M | $24.25M |
| Net Income | -$9.63M | -$9.21M |
| EPS Diluted | -$0.23 | — |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Alnylam Pharmaceuticals, Inc. · CIK 1178670 · Engraved from SEC EDGAR
